Protein Kinase C Signaling in Cancer Biology

Protein Kinase C (PKC) comprises a family of serine/threonine kinases that translate lipid and calcium signals into diverse cellular outcomes. Activated by diacylglycerol and, for certain isozymes, calcium, PKC enzymes undergo conformational change and translocate to membrane compartments where they phosphorylate substrates involved in proliferation, survival, migration and angiogenesis. Aberrant PKC signalling is implicated in tumour initiation and progression through isozyme-specific regulation of growth factor receptors, mitogen-activated protein kinase cascades and apoptosis pathways. Some PKC isozymes exert protumourigenic effects by stabilising oncogenic transcription factors, whereas others act as tumour suppressors by facilitating programmed cell death. The context-dependent roles of individual isozymes reflect differences in expression patterns, subcellular localisation and interacting partners. Recent efforts have sought isozyme-selective modulators to avoid the toxicity and limited efficacy of broad-spectrum inhibitors. Advances in structural biology and membrane-mimetic systems have uncovered allosteric sites and lipid-binding modes that inform rational drug design, offering the prospect of fine-tuning PKC activity for targeted cancer therapy.

Research from Nature Portfolio

Long-timescale molecular dynamics simulations have revealed that distinct PKC activators impose unique orientations and depths of insertion for the kinase–ligand complex within lipid bilayers. By comparing endogenous diacylglycerol mimetics and natural product analogues, researchers have demonstrated how subtle differences in ligand structure modulate water networks at the membrane interface, thereby stabilising alternative active conformations. These insights provide a conceptual framework for the design of simplified, membrane-competent agonists and antagonists that achieve isozyme selectivity through tailored membrane engagement rather than solely targeting the catalytic cleft.

Protein Kinase C Signaling in Cancer Biology publication trend

The graph below shows the total number of articles in protein kinase c signaling in cancer biology across all publications each year (not limited to Nature Index journals).

Technical terms

Diacylglycerol (DAG): A membrane-associated lipid second messenger that binds the C1 domain of PKC to promote recruitment and activation at the plasma membrane.

C1 domain: A conserved cysteine-rich motif in novel and conventional PKC isozymes responsible for recognising diacylglycerol and phorbol esters.

Isozyme: A distinct enzyme variant within the PKC family that shares catalytic activity but differs in regulatory domains, subcellular localisation and tissue expression.

Autoinhibition: A regulatory mechanism whereby intramolecular interactions maintain PKC in an inactive state until displaced by co-factors such as lipid or calcium.

Phorbol ester: A plant-derived analogue of diacylglycerol used experimentally to activate PKC by binding to the C1 domain and mimicking physiological lipid signals.

References

1. Molecular dynamics simulations reveal ligand-controlled positioning of a peripheral protein complex in membranes. Nature Communications (2017).
2. Expanding the Paradigm of Structure-Based Drug Design: Molecular Dynamics Simulations Support the Development of New Pyridine-Based Protein Kinase C‑Targeted Agonists. Journal of Medicinal Chemistry (2023).
3. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. Journal of Biological Chemistry (1991).